Current treatments for acute myelogenous leukemia (AML) have not proven very effective, particularly when patients are elderly or already infirm. This collection of articles addresses new and promising research into the molecular pathogenesis and physiology of AML, including information on drug resistance transporters and DNA damage response, new molecular therapies such as FLT2 and the modulation of gene expression, and molecular therapeutics of AML in selected target approaches. Several articles address special challenges in research and treatment such as children and elderly patients, and articles also address critical factors in leukemia cell survival and drug resistance and their potential exploitation as therapeutic targets. Annotation ©2007 Book News, Inc., Portland, OR (booknews.com)